In the evening edition of Yomiuri Shimbun on August 5th, 2020 (Page 10), a research activity of the team led by Professor Hiroshi Kawamoto, the Vice Director of Institute for Frontier Life and Medical Sciences, Kyoto University and an executive director of Rebirthel, was introduced.
In the article entitled “Research to develop a therapy for the novel coronavirus infection using iPS cells”, it is reported that his team will launch a research project to develop a therapy using killer T cells that are regenerated from iPS cells. This therapy can provide “off-the-shelf” T cell preparation while the current method is time-consuming where killer T cells are collected from a patient and returned after being cultured in vitro. His team aims to start a clinical trial in 2 years.
Link to the article (Available to members and only in Japanese)